Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Evaluation Of hOCT1expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line

Cintia Do Couto Mascarenhas, PhD, Maria Helena Almeida, PhD, Eliana C M Miranda, MEd, Bruna Virgilio, Marcia Torresan Delamain, MD, Gislaine O. Duarte, PhD, Vagner O Duarte, Carmino A De Souza, Sr., MD, PhD, Katia B. Pagnano, MD, PhD

Blood (2013) 122 (21): 4041.

https://doi.org/10.1182/blood.V122.21.4041.4041

Published: 2013

Journal Articles

Transcriptome of Expressed Genes in CD34+ and CD66b+ Chronic Myeloid Leukemia Cells and Its Potential Role in the Transport of Kinase Inhibitors

Caroline Fátima Aquino Moreira-Nnes, MsC, Ana Cristina Simões Beltrão, MD, MSc, Tereza Cristina Brito Azevedo, MD, MSc, Larissa Tatiana Valente Martins Francês, MD, MSc, Rodrigo Guarischi Mattos Amaral Sousa, MSc, Israel Tojal Silva, PhD, Artur Luiz Costa Silva, PhD, Wilson Araújo Silva-Jr, PhD, José Alexandre Rodrigues Lemos, PhD

Blood (2011) 118 (21): 4426.

https://doi.org/10.1182/blood.V118.21.4426.4426

Published: 2011

Journal Articles

Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients

Blood (2010) 116 (21): 671.

https://doi.org/10.1182/blood.V116.21.671.671

Published: 2010

Journal Articles

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34 + cells

Jane R. Engler, Amity Frede, Verity Saunders, Andrew Zannettino, Deborah L. White, Timothy P. Hughes

Blood (2010) 116 (15): 2776–2778.

https://doi.org/10.1182/blood-2010-01-267013

Published: 2010

Journal Articles

OCT-1 Activity in CML CD34+ Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity.

Jane R Engler, Amity Frede, Verity A Saunders, Andrew Christopher William Zannettino, BSc, PhD, Deborah L White, Timothy P. Hughes, MD

Blood (2009) 114 (22): 2189.

https://doi.org/10.1182/blood.V114.22.2189.2189

Published: 2009

Journal Articles

Prognostic Significances of ABCG-2 and hOCT-1 Gene Expression in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Yeo-Kyeoung Kim, Hee-Nam Kim, Jae-Sook Ahn, Deok-Hwan Yang, Il-Kwon Lee, Je-Jung Lee, Hyeoung-Joon Kim

Blood (2009) 114 (22): 3299.

https://doi.org/10.1182/blood.V114.22.3299.3299

Published: 2009

Journal Articles

Analysis of Genetic Variants and Expression Levels of Human Organic Cation Transporter 1 (HOCT1) and Genetic Variants in MDR1 in CML: Weak Associations Were Detected but a Major Role in Clinical Response to Imatinib Resistance Is Unlikely

Susanne Schnittger, PhD, Sonja Rauhut, Claudia Tschulik, Madlen Ulke, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2008) 112 (11): 3203.

https://doi.org/10.1182/blood.V112.11.3203.3203

Published: 2008

Journal Articles

Effect of hOCT1 Polymorphism on Imatinib Mesylate Action in CML Patients

Huanling Zhu, MD, Nan Hu, MD, Ting Liu, MD, Chunxue Zeng, MD, Wentong Meng

Blood (2008) 112 (11): 4257.

https://doi.org/10.1182/blood.V112.11.4257.4257

Published: 2008

Journal Articles

Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients

Jane R Engler, Amity Frede, Andrew C W Zannettino, PhD, Deborah L White, PhD, Timothy P Hughes, MD

Blood (2008) 112 (11): 196.

https://doi.org/10.1182/blood.V112.11.196.196

Published: 2008

Journal Articles

Prognostic Significance of hOCT1 and ABCG2 Expression in Chronic Myeloid Leukemia Patients Treated with Imatinib

Yeo-Kyeoung Kim, Hee-Nam Kim, Ri Yu, Il-Kwon Lee, Jae-Sook Ahn, Deok-Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim

Blood (2008) 112 (11): 5033.

https://doi.org/10.1182/blood.V112.11.5033.5033

Published: 2008

Journal Articles

Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib

Hélène Labussière, MD, Sandrine Hayette, PhD, Kaddour Chabane, BSc, Marie-Claude Gagnieu, PharmD, Quoc-Hung Lê, MD, PhD, Isabelle Tigaud, MD, Joëlle Bernard, BSc, Fiorenza Barraco, MD, Jean-Pierre Magaud, MD, PhD, Mauricette Michallet, MD, PhD, Franck E Nicolini, MD, PhD

Blood (2008) 112 (11): 2643.

https://doi.org/10.1182/blood.V112.11.2643.2643

Published: 2008

Journal Articles

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

Athina Giannoudis, Andrea Davies, Claire M. Lucas, Robert J. Harris, Munir Pirmohamed, Richard E. Clark

Blood (2008) 112 (8): 3348–3354.

https://doi.org/10.1182/blood-2007-10-116236

Published: 2008

Journal Articles

Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.

Andrea Davies, PhD, Athina Giannoudis, PhD, Claire M. Lucas, BSc, Robert J. Harris, PhD, Paul W. Manley, PhD, Munir Pirmohamed, PhD, FRCP, FRCP(E), Richard E. Clark, MA, MD, FRCP, FRCPat

Blood (2007) 110 (11): 2364.

https://doi.org/10.1182/blood.V110.11.2364.2364

Published: 2007

Journal Articles

Unlike Imatinib, Dasatinib Uptake into Chronic Myeloid Leukaemia Cells Is Independent of hOCT1 Expression.

Athina Giannoudis, PhD, Andrea Davies, PhD, Claire M. Lucas, BSc, Robert J. Harris, PhD, Munir Pirmohamed, PhD, FRCP, FRCP(E), Richard E. Clark, MA, MD, FRCP, FRCPat

Blood (2007) 110 (11): 3458.

https://doi.org/10.1182/blood.V110.11.3458.3458

Published: 2007

Journal Articles

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Gene Polymorphisms To Predict Response and Resistance to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia.

Dong Hwan (Dennis) Kim, MD, PhD, Lakshmi Sriharsha, Wei Xu, Suzanne Kamel-Reid, Xiangdong Liu, Katherine Siminovitch, Hans Messner, Jeffrey Lipton

Blood (2007) 110 (11): 737.

https://doi.org/10.1182/blood.V110.11.737.737

Published: 2007

NARROW

Evaluation Of hOCT1expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line

Transcriptome of Expressed Genes in CD34+ and CD66b+ Chronic Myeloid Leukemia Cells and Its Potential Role in the Transport of Kinase Inhibitors

Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34 + cells

OCT-1 Activity in CML CD34+ Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity.

Prognostic Significances of ABCG-2 and hOCT-1 Gene Expression in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Analysis of Genetic Variants and Expression Levels of Human Organic Cation Transporter 1 (HOCT1) and Genetic Variants in MDR1 in CML: Weak Associations Were Detected but a Major Role in Clinical Response to Imatinib Resistance Is Unlikely

Effect of hOCT1 Polymorphism on Imatinib Mesylate Action in CML Patients

Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients

Prognostic Significance of hOCT1 and ABCG2 Expression in Chronic Myeloid Leukemia Patients Treated with Imatinib

Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.

Unlike Imatinib, Dasatinib Uptake into Chronic Myeloid Leukaemia Cells Is Independent of hOCT1 Expression.

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Gene Polymorphisms To Predict Response and Resistance to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only